Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pollinex Quattro
- Development stage
- Unknown
- Lead developer
- Allergy Therapeutics
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Pollinex Quattro is an ultra-short-course subcutaneous immunotherapy (SCIT) vaccine designed for the treatment of seasonal allergic rhinitis and rhinoconjunctivitis caused by grass, tree, or ragweed pollen. The formulation consists of chemically modified allergens (allergoids) that are adsorbed onto L-tyrosine to form a depot for slow release and improved tolerability. It incorporates the adjuvant monophosphoryl lipid A (MPL), which enhances efficacy by promoting a Th1-type immune response—raising allergen-specific IgG levels while dampening IgE responses during allergen exposure. The therapy is administered as four preseasonal injections and has demonstrated clinical efficacy in reducing symptoms and medication use in children, adolescents, and adults with pollen allergies[2][3][5][9].
- Brand names
- Pollinex Quattro
- Other names
- MPL-containing Pollinex allergy desensitization vaccineQuattro MPLRagweed SC vaccine
02
Targets
BCR (Immunoglobulin G B Cell Receptor)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on Pollinex Quattro.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pollinex Quattro.